What are the side effects of Jakavi 5mg?

Side effects of Jakavi tablet are diarrhea, low platelet count, fatigue or tiredness, anemia and bleeding. Visit the doctor if any of the symptoms persist.

What precautions are taken while using Jakavi 5mg tablet?

Jakavi 5mg tablet should be taken under proper medical guidance, regular checkups and appointments. Consult the doctor to ensure safe treatment option.

Who can take Jakavi 5mg tablet?

Jakavi 5mg tablet should be taken by the patient of blood disorders with mainly chronic idiopathic myelofibrosis and polycythemia vera.

What is the active ingredient of Jakavi 5mg tablet?

The active ingredient of Jakavi tablet is Ruxolitinib that helps to treat blood disorders by using certain enzyme to inhibit the production of cancer cells in the body.

Buy Jakavi 5mg Tablet Online: Price, 9% Discount, Uses, and Side Effects

Name: Jakavi 5mg Tablet
Brand: Jakavi
Price: 22136 INR
Availability: InStock
Rating: 4.57 (7 reviews)

Description

Jakavi 5mg tablet is a targeted therapy prescribed by the healthcare professional. It is used in the treatment of several disorders, including chronic idiopathic myelofibrosis and polycythemia.

Its active ingredient is Ruxolitinib which belongs to the drug class of janus kinase inhibitors and it works by blocking specific enzyme that contribute to abnormal cell growth and inflammation. The medicine dosage and duration is correctly administration by healthcare professional.

Uses

Treat blood disorders such as chronic idiopathic myelofibrosis and polycythemia.

Side Effects

Every medication has several side effects some are resolved on their own and some need proper medical attention to treat. Common ones include:

Low red and white blood cell counts
Low platelet counts
Dizziness, headache
Bruising
Diarrhea
Infections including viral infections
Swelling in the face and body
Fatigue or tiredness

Severe infections like hepatitis B
Anemia
Bleeding

How To Use

Jakavi 5mg tablet should be taken with or without food at the fixed time everyday to enhance the effectiveness of the medication.
Proper dosage and duration is correctly administered by the healthcare professional, do not self administered.
To get the most benefit, always follow the recommended dosage and duration and consult your doctor if you experience any of the side effects to ensure safe and effective treatment option.

How It Works

The medicine targets and inhibits JAK1 and JAK2 enzyme which plays a key role in immune response signaling, blood cell production and inflammation. By blocking these signals, jakavi 5mg tablet helps calm abnormal cell growth in myeloproliferative disorders and reduces inflammatory activity.

The tablet is used as a first line therapy that stops the growth of cancer cells and protect the body from spreading tumor cells.

Safety Advice

Alcohol

If you are an alcoholic person, avoid using it as it interrupts with the treatment when using Jakavi 5mg tablet.

Pregnancy

Pregnant women should avoid using Jakavi 5mg tablet because it may interrupt with the pregnancy symptoms and harm the fetus in several ways.

Breast Feeding

Jakavi 5mg tablet is not recommended for breastfeed women as the tablet is passed through breast which is harmful for the baby.

Driving

Jakavi 5mg tablet may cause dizziness and loss of vision ability. Consult with the doctor for proper medical attention.

Kidney

Kidney patients must consult the doctor before using Jakavi 5mg tablet. It may interfere with the kidney function.

Liver

Jakavi 5mg tablet should disrupt the liver function. It can be correctly administered by a healthcare professional.

FAQs

Jakavi 5mg tablet blocks the JAK1 and JAK2 enzyme which is responsible for the growth of cancer cells and helps calm abnormal cell growth in myeloproliferative disorders and reduces inflammatory activity.

References

Savoia, M., Pugliese, S., Teseo, G., Pennacchia, A., Ricci, M., Ronca, S., ... & D’arpino, A. (2021). 3PC-067 Key role of the hospital pharmacy in a non-profit study involving ruxolitinib 5 mg CPS: implementation and quality assurance of an investigational manufacturing product.
Plosker, G. L. (2015). Ruxolitinib: a review of its use in patients with myelofibrosis. Drugs, 75(3), 297-308.
Torrente-López, A., Hermosilla-Fernández, J., Hernández-Jiménez, J., Cabeza, J., Salmerón-García, A., & Navas, N. (2021). 3PC-065 Impact of light stress on the isoform profile of nivolumab (Opdivo) in opened vials estimated by (RP) UHPLC-UV-(HESI/Orbitrap)-MS.
Witte, T. (2022). Januskinaseinhibitoren. Zeitschrift für Rheumatologie, 81(2), 94-99.
WAEC, N., & a Doctor, C. Jakavi 5mg Tablet 14? S.

Jakavi 5mg Tablet

About The Product